A Study to Evaluate the Effect of Volanesorsen on Cardiac Repolarization Conducted in Healthy Volunteers
Status:
Completed
Trial end date:
2016-12-20
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess the corrected QT interval (QTc) effect of
volanesorsen (ISIS 304801) administered as a 300 mg subcutaneous (SC) therapeutic and a 300
mg intravenous (IV; 2-hour infusion) supra-therapeutic dose relative to placebo in healthy
adult male and female subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Ionis Pharmaceuticals, Inc.
Collaborator:
Akcea Therapeutics
Treatments:
Fluoroquinolones Moxifloxacin Norgestimate, ethinyl estradiol drug combination